سعر برنتيليكس 20 مجم 2024

Brintellix 20 mg film-coated tablets ×14 (Lundbeck / Multipharma). Vortioxetine for major depressive disorder in adults.

• Treatment of major depressive disorder (MDD) in adults.Population: AdultsDailyMed / FDA

• Most common (≥5% and ≥2× placebo): nausea, constipation, vomiting. Nausea is dose-related and often early.International label, same formulation · DailyMed / FDA

• Hypersensitivity to vortioxetine or any component (anaphylaxis, angioedema, urticaria reported).International label, same formulation · DailyMed / FDA
• Do not use with MAOIs intended to treat psychiatric disorders or within 21 days of stopping vortioxetine; do not use within 14 days of stopping an MAOI. Do not start in patients on linezolid or IV methylene blue.International label, same formulation · DailyMed / FDA

• Boxed warning: increased risk of suicidal thoughts and behaviors in pediatric and young adult patients; closely monitor all patients especially early in treatment and at dose changes. Not approved in pediatrics.International label, same formulation · DailyMed / FDA
• Serotonin syndrome risk with other serotonergic agents. Increased bleeding risk with NSAIDs/aspirin/anticoagulants. Activation of mania/hypomania — screen for bipolar disorder. Discontinuation symptoms possible at 15–20 mg/day. Angle-closure glaucoma risk. Hyponatremia/SIADH. Sexual dysfunction.International label, same formulation · DailyMed / FDA

• MAOIs / linezolid / IV methylene blueMajorContraindicated — serotonin syndrome risk.DailyMed / FDA
• Strong CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine, quinidine)MajorReduce vortioxetine dose by half.DailyMed / FDA
• Strong CYP inducers (rifampin, carbamazepine, phenytoin)ModerateConsider increasing vortioxetine dose (max 3× original) if coadministered >14 days.DailyMed / FDA

• Limited human data. Third-trimester SNRI/SSRI exposure associated with neonatal complications and possible PPHN; possible increased postpartum hemorrhage. Advise of potential fetal risk.International label, same formulation · DailyMed / FDA
• Unknown if present in human milk; present in rat milk. Weigh benefits of breastfeeding vs maternal need and potential infant effects.International label, same formulation · DailyMed / FDA

• Vortioxetine: Enhances serotonergic activity via 5-HT reuptake inhibition; also 5-HT3 antagonist and 5-HT1A agonist (contribution to effect not fully established).